There is limited data on the use of tirzepatide in pregnant women
Medicare Part D explicitly prohibits coverage for drugs used for weight loss under federal law, though legislative efforts continue to push for change
European Journal of Clinical Investigation, 38 (10), 743751
In particular, the SURMOUNT-1 trial demonstrated that patients on tirzepatide experienced up to 22.5% weight loss , while semaglutide users typically averaged around 15% at the highest dose
While GLP-1 and GIP perform similar actions for blood sugar control and fat metabolism as semaglutide, retatrutide also activates GCG which primarily benefits gut health and nutrient absorption
They can offer guidance based on your medical history, ensuring the best treatment for your condition